ORKA (Oruka Therapeutics) Construction In Progress : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Construction In Progress?

Oruka Therapeutics Construction In Progress Historical Data

The historical data trend for Oruka Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Construction In Progress Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Construction In Progress

Oruka Therapeutics Semi-Annual Data
	Dec24
Construction In Progress	-

Oruka Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.